ANGPT2 and neoplasm: Wu and colleagues identified a subset of melanoma patients characterized by a significant tumor infiltration of CD68+ macrophages that particularly responded to treatment with Ipilimumab and Bevacizumab with a neat decrease in ANG-2 expression (68).